KRAS and familial pancreatic carcinoma: A recent multicenter prospective study by Bournet et al. [58] using biopsies obtained from EUS-FNA found that in particular, the KRAS G12D mutant is promising as an independent marker and progress predictor of advanced pancreatic cancer cases.